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Background: The human gut houses one of the most complex and abundant ecosystems composed of up to
1013-1014 microorganisms. The importance of this intestinal microbiota is highlighted when a disruption of the
intestinal ecosystem equilibrium appears (a phenomenon called dysbiosis) leading to an illness status, such as
inflammatory bowel diseases (IBD). Indeed, the reduction of the commensal bacterium Faecalibacterium prausnitzii
(one of the most prevalent intestinal bacterial species in healthy adults) has been correlated with several diseases,
including IBD, and most importantly, it has been shown that this bacterium has anti-inflammatory and protective
effects in pre-clinical models of colitis. Some dysbiosis disorders are characterized by functional and physiological
alterations. Here, we report the beneficial effects of F. prausnitzii in the physiological changes induced by a chronic
low-grade inflammation in a murine model. Chronic low-grade inflammation and gut dysfunction were induced in mice
by two episodes of dinitro-benzene sulfonic acid (DNBS) instillations. Markers of inflammation, gut permeability, colonic
serotonin and cytokine levels were studied. The effects of F. prausnitzii strain A2-165 and its culture supernatant (SN) were
then investigated.
Results: No significant differences were observed in classical inflammation markers confirming that inflammation was
subclinical. However, gut permeability, colonic serotonin levels and the colonic levels of the cytokines IL-6, INF-γ, IL-4 and
IL-22 were higher in DNBS-treated than in untreated mice. Importantly, mice treated with either F. prausnitzii or its SN
exhibited significant decreases in intestinal permeability, tissue cytokines and serotonin levels.
Conclusions: Our results show that F. prausnitzii and its SN had beneficial effects on intestinal epithelial barrier
impairment in a chronic low-grade inflammation model. These observations confirm the potential of this bacterium as a
novel probiotic treatment in the management of gut dysfunction and low-grade inflammation.
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The human gastrointestinal tract (GIT) is one of the
most complex ecosystems. The interaction between GIT
microbiota and the host is indispensable for the maturation
of the immune system and for the regulation of intestinal
physiology [1]. Firmicutes (which encompasses Clostridum
leptum and C. coccoides) and Bacteroidetes are the two
dominant phyla in the human gut, representing 90% of the* Correspondence: philippe.langella@jouy.inra.fr; luis.bermudez@jouy.inra.fr
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unless otherwise stated.microbiota, with Actinobacteria being the third, comprising
of only 3% [2].
When the normal microbial ecosystem is disrupted,
different non-predominant bacteria can bloom, consti-
tuting a potential trigger for disease. The term dysbiosis
refers to a type of microbial imbalance that may pro-
mote disease. The strongest relationship between dysbio-
sis and pathological condition has been observed in
inflammatory bowel diseases (IBD), where the propor-
tion of Firmicutes is lower than in healthy subjects [3,4].
IBD, composed mainly of ulcerative colitis (UC) and
Crohn’s disease (CD), are characterized by an unusualThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chronic inflammation of the gut with a mix of remission
and exacerbation periods. It has recently been suggested
that the colonic microbiota is also abnormal in patients
with irritable bowel syndrome (IBS), with a 2-fold in-
creased ratio of the Firmicutes to Bacteroidetes [5]. IBS
is a symptom-based diagnosis characterized by chronic
abdominal pain and altered bowel habits [6] in the ab-
sence of detectable structural abnormalities [7].
IBD and IBS are classically considered as dichotomous
conditions. However, increasing evidence, such as the in-
volvement of brain-gut axis dysfunction [8-10], as well
as abnormal microbiota, supports some pathogenetic
overlap between the two conditions [8]. Furthermore,
the identification of low-grade inflammation [9], histo-
pathological observations and mucosal cytokine levels in
the colon of a subset of IBS patients [10,11] and the pres-
ence of IBS-like symptoms in quiescent IBD [8,12-14]
support this hypothesis.
Low-grade inflammation can persist in many IBD pa-
tients who have otherwise obtained clinical remission
[15], as well as barrier alterations due to functional
impairment of tight junction proteins [16]. In fact, im-
paired gut barrier function appears to precede the devel-
opment of IBD [17] and increased epithelial permeability
causes mucosal immune activation predisposing or en-
hancing disease progression [18].
Due to the importance of the microbiota in the devel-
opment of these dysbiosis-related diseases, there is
currently increasing interest in the development of
microbiota-modulating therapies, including the use of
probiotics [19,20]. F. prausnitzii is a candidate probiotic
bacterium that has been proposed as a sensor of intes-
tinal health [21]. Changes in the abundance of this com-
mensal anti-inflammatory bacterium [22] and major
member of the Clostridium leptum group [23] have been
linked to dysbiosis in several human disorders [21], such as
IBD, where a low abundance was found in patients exhibit-
ing endoscopic recurrence 6 months after surgery [3].
Furthermore, the recovery of F. prausnitzii counts after
relapse is associated with maintenance of clinical remission
in UC patients [24]. Besides, F. prausnitzii has shown pro-
tective effects in inflammation parameters in both acute
[22] and chronic [25] models of chemical-induced active in-
flammation; however its beneficial role during low-grade
inflammation and gut dysfunction has not been tested yet.
For these reasons, we hypothesized a possible protective
role of F. pausnitzii on gut dysfunction mediated by
low-grade inflammation. Therefore, we investigated the
potential of F. prausnitzii as a probiotic for gut dysfunction
prevention and therapy. We tested the effects of F. praus-
nitzii in a murine model of chronic low-grade inflammation
mimicking some of the most common gut dysfunction pa-
rameters found in IBD patients under remission.Results
Validation of a low-grade inflammation model in
DNBS-treated mice
The model of low-grade DNBS inflammation developed
in this study involves the induction of a low grade, sub-
clinical inflammatory status, followed by a recovery
period and a reactivation period mimicking the relapsing
nature in IBD (Figure 1A). The challenge with a sub-
colitic DNBS dose (i.e. second DNBS administration) did
not induce important changes in weight or colonic
macroscopic or histological scores confirming the ab-
sence of a strong inflammation (Figure 1B, C, E, G, H).
The degree of infiltration by polymorphonuclear neutro-
phils, as measured by tissue MPO activity, as well as
Lipocalin-2 (Lcn-2), an early inflammation marker in in-
flammatory and autoimmune disorders, did not differ
significantly between DNBS-treated and control animals
(Figure 1D, F). These observations suggest that DNBS-
treated mice tend to display a low-grade inflammatory
status rather than a strong inflammation (as observed
in IBD patients) thereby validating our model for further
analysis of physiological changes induced by this chronic
low-grade, subclinical inflammation. The findings for all
these markers thus suggest that the colons of DNBS-
treated mice have a low-grade inflammatory status. Com-
parison of the levels of these markers with those previously
published by our group following a colitic dose of DNBS
that induced severe or moderate chronic inflammation [25]
provided further evidence that this protocol leads to low-
grade inflammatory conditions (Figure 2).
Faecalibacterium prausnitzii A2-165 and its SN counteract
DNBS-induced hyperpermeability in vivo
The gut of DNBS-treated mice showed high permeability
to the paracellular tracer FITC-dextran in vivo (Kruskal-
Wallis test followed by a Dunn’s Multiple Comparison
test, p < 0.05) (Figure 3A). We tested whether F. praus-
nitzii modulates this DNBS-induced gut dysfunction.
Treatment with either F. prausnitzii or its SN resulted
in a significant reduction of intestinal permeability
(Kruskal-Wallis test followed by a Dunn’s Multiple
Comparison test, p < 0.05) (Figure 3A). To confirm
that these findings corresponded to local paracellular
translocation (i.e. in the colon) of the FITC-dextran
in vivo in this model, intestinal permeability was
assessed in vitro in colonic samples mounted in Ussing
chambers extracted from mice at sacrifice (Figure 3B).
The results were consistent with the pattern ob-
served in vivo (Kruskal-Wallis test followed by a
Dunn’s Multiple Comparison test, p < 0.05) confirm-
ing local translocation of the FITC-dextran. We then
tested F. prausnitzii SN (which had a large effect on
intestinal permeability in vivo) with samples from





Figure 1 Experimental protocols for the mouse model of chronic micro-inflammation and absence of inflammation. A) Colitis was
induced by intrarectal administration of 100 mg/Kg of DNBS in solution in 30% ethanol (EtOH). Control mice (without colitis) received only 30%
EtOH. The effects of DNBS are highest during the first 3 days after its administration (DNBS period). Ten days after the end of the DNBS period,
bacterial culture, PBS, or supernatant (SN) were intragastrically administered daily for 10 days (gavage period). Colitis was reactivated 21 days after
the first DNBS injection with a second injection of 50 mg/Kg of DNBS solution. Three days after reactivation mice were sacrificed. The severity of
the reactivated colitis was assessed from difference in body weight (B), macroscopic score (C), MPO activity (D), histological score (E) (n = 16
mice per group) and lipocalin-2 levels (F) (n = 2*4 = 8 mice per group) between control non-inflamed (EtOH-PBS), control inflamed (DNBS-PBS),
bacteria-free culture medium (DNBS-LYBHI), F. prausnitzii strain A2-165 (DNBS-Fprau), and F. prausnitzii A2-165 SN (DNBS-SN) groups. Experiments
were performed at least in duplicate. Normal appearance of the colon of a control mouse with no inflammation (G) and of a mouse with
micro-inflammation (H).
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Sample/hr/cm2, was lower with SN than PBS (Kruskal-
Wallis test followed by a Dunn's Multiple Compari-
son test, p < 0.05) (Figure 3B). No significant differ-
ences were obtained in tissue conductance (mS/cm2)
(Figure 3C).F. prausnitzii restores DNBS-induced apical junction
proteins decrease
These effects on gut permeability prompted us to investi-
gate the involvement of epithelial adherens junction (AJ)
and tight junction (TJ) proteins, by assaying for relevant
mRNA levels. The mRNA levels for Claudin-4 (Kruskal-
A B
C D
Figure 2 Comparison of inflammation measures in severe and moderate colitis models [25] with the micro-inflammation model
employed in this study. Severity of the colitis was assessed from differences in body weight (A), macroscopic score (B), histological score (C)
and MPO activity (D) between the control non-inflamed (EtOH-PBS), control inflamed severe colitis model (DNBS-PBS (S-I)) [25], moderate colitis
model (DNBS-PBS (M-I)) [25] and micro-inflammation model (DNBS-PBS (Mi-I)). Experiments were performed at least in duplicate. Comparisons
involved the non-parametric Kruskal-Wallis test was used followed by a Dunn’s Multiple Comparison test. *p < 0.05 vs. DNBS-PBS, +p < 0.05
(n = 16 mice per group).
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p = 0.0175), F11r (JAM1) (Kruskal-Wallis test, p = 0.0023),
Occludin (Kruskal-Wallis test, p = 0.0170) and ZO-1
(Kruskal-Wallis test, p = 0.0001) were all less abundant in
DNBS-treated mice than in control mice (Kruskal-Wallis
test followed by a Dunn’s Multiple Comparison test,
p < 0.05) (Figure 4); Claudin-1, 2, 5 and 15 mRNA levels
were unaffected (data no shown). F. prausnitzii and its SN
tended to normalize the amounts of all these mRNA tran-
scripts, the only statistically significant regulation was found
for Claudin-4 and F11r (Kruskal-Wallis test followed by a
Dunn’s Multiple Comparison test, p < 0.05) (Figure 4).
Claudin-4, E-cadherin, F11r and Occludin expression was
also analyzed by immunofluorescence (Additional file 1:
Figure S1). Staining for the four proteins was reduced in
DNBS + PBS mice compared to EtOH+ PBS group
(Additional file 1: Figure S1). According to the qPCR
results, F. prausnitzii tends to increase the expression of all
the proteins.A systemic and mucosal reduction in pro-inflammatory
cytokine production correlates with the protective effects
of F. prausnitzii and its SN after DNBS challenge
We investigated the cytokines involved in this low-grade
inflammation model and the mechanism by which F.
prausnitzii and its SN protect the intestinal mucosa. We
assayed 13 cytokines (including those involved in the Th1,
Th2, Th17 and Th22 pathways) in both colonic and serum
samples after the second DNBS injection (Figure 5). The
concentrations of IL-13, IL-1α, IL-6, IL-22, IL-2, IL-27, IL-
4, IFN-γ, and TNF-α in colon samples were higher in
DNBS-treated mice than in controls (Figure 5A and data
not shown), consistent with local inflammation. Similarly,
cytokine concentrations in serum samples were consistent
with the low-grade inflammatory status (Figure 5B and data
not shown). Strikingly, the concentration of IL-6, IFN-γ
and IL-4 in colon samples and of IL-6 and IL-22 in serum
was statistically significantly reduced by treatment with ei-
ther F. prausnitzii or its SN (Kruskal-Wallis test followed
Figure 3 In vivo and in vitro permeability measurements. For in vivo measurements of gut permeability, animals were orally gavaged with
FITC-dextran (A) (n = 16 mice per group). For in vitro measures, sections of colon were mounted in Ussing chambers and 51Cr-EDTA flux (% Hot
Sample/hr/cm2) (B) and tissue conductance (mS/cm2) (C) were measured (n = 6 mice per group). Control non-inflamed (EtOH-PBS), control
inflamed (DNBS-PBS), bacteria-free culture medium (DNBS-LYBHI), F. prausnitzii strain A2-165 (DNBS-Fprau), and F. prausnitzii A2-165 SN (DNBS-SN)
groups. Experiments were performed at least in duplicate. Comparisons involved the non-parametric Kruskal-Wallis test was used followed by a
Dunn’s Multiple Comparison test. *p < 0.05 vs. DNBS-PBS, +p < 0.05.
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were clear tendencies for these treatments to reduce
colonic IL-22 and serum IL-13 concentrations (Figure 5).
F. prausnitzii and its SN restore serotonin variations
observed in DNBS-treated mice
Serotonin (also called 5-HT for 5-hydroxyptamine) of
the key neurotransmitters in the GIT, and affects motil-
ity, sensation and secretion [26]. We therefore studied
serotonin concentrations in colon tissue and content by
ELISA. Both colonic (Figure 6A) and colon content
(Figure 6B) serotonin concentrations were higher in
DNBS-treated mice than EtOH-treated controls (Kruskal-
Wallis test followed by a Dunn’s Multiple Comparison
test, p < 0.05). Treatments with both F. prausnitzii and
its SN counteracted these increases (Kruskal-Wallis test
followed by a Dunn’s Multiple Comparison test, p < 0.05)
(Figure 6A, B). Serotonin reuptake transporter (SERT)
mRNA was assayed by qPCR in colon tissues: the value
for inflamed mice was half than for control non-inflamed
mice (2-ΔΔCt = 0.49); the value for mice treated with F.
prausnitzii was the same as that for normal healthy mice
(2-ΔΔCt = 1.09 vs. EtOH-PBS). Similar positive effects were
found in SN-treated mice (2-ΔΔCt = 1.29 vs. EtOH-PBS)
although the culture medium (LYBHI) itself had a positive
effect (2-ΔΔCt = 0.98 vs. EtOH-PBS).Discussion
There is growing evidence pointing at the role of the gut
microbiota in the development of IBD [3,4]. Further-
more, at least 40% of IBD patients in clinical remission
have ongoing histological evidence of inflammation [15]
and suffer from altered gut functions with the
involvement of brain-gut axis dysfunction [8,26,27].
Interestingly, previous transient or chronic inflammation
can lead to persistent gut dysfunction [28] and it has
been suggested that the host microbiota may affect the
two-ways communication pathway between the gut and
the brain [29].
Because the microbiota is a determinant of normal gut
function and immunity [30], and because there is evi-
dence of dysbiosis in IBD, there is increasing interest in
the development of new adjuvant therapies based on
modulation of the microbiota [31]. The traditional
probiotic approach based on lactic acid bacteria (LAB)
strains can be now extended to new candidate beneficial
bacteria from the intestinal microbiota, including F.
prausnitzii. This metabolic active species is a member of
the C. leptum group, and is one of the most prevalent
commensal bacteria in the human gut [2], involved in
colonic epithelial physiology [32], and a reduction in its
abundance has been observed in IBD patients [24].
The anti-inflammatory properties of the F. prausnitzii
Figure 4 Effect of F. prausnitzii on apical junction proteins mRNAs in a DNBS-induced low-grade inflammation model. Apical junction
protein expression levels were determined by real-time qPCR. Control non-inflamed (EtOH-PBS), control inflamed (DNBS-PBS), bacteria-free culture
medium (DNBS-LYBHI), F. prausnitzii strain A2-165 (DNBS-Fprau), and F. prausnitzii A2-165 SN (DNBS-SN) groups. Experiments were performed at
least in duplicate. Comparisons involved the non-parametric Kruskal-Wallis test was used followed by a Dunn’s Multiple Comparison test. *p < 0.05
vs. DNBS-PBS, +p < 0.05 (n = 6 mice per group).
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in various cellular models and validated in vivo in mur-
ine models of TNBS-induced acute colitis [22] and
DNBS-induced chronic severe and moderate colitis [25].
We investigated the beneficial effects of both F.
prausnitzii and its filtered SN (with the consequent loss
of high molecular weight molecules) using a chronic
low-grade inflammatory model, which mimics gut dys-
function related to colonic low-grade inflammation
[11,12]. We adjusted the dose of DNBS such that the
challenge induced low-grade inflammation, as it has been
described for TNBS [33], a model that resembles DNBS
[34]. To mimic the relapsing character of IBD and reach a
remission status, we used a chronic protocol with recovery
and reactivation periods. Our results show that chronic,
low-dose administration of DNBS did not induce severe
colonic inflammation: there was no macro- or micro-
scopic damages or granulocyte infiltration. Further-
more, no increase in the levels of lipocalin 2 (Lcn-2),
an early marker of inflammation, was observed [35].
Lcn-2 is an innate immune protein produced by a var-
iety of cells, and its levels are increased during several
pathologic conditions, including immune complex-
mediated inflammatory or autoimmune disorders [36,37].These various results indicate the absence of any
substantial active inflammatory tone in this DNBS-
treated mouse model. However, the presence of a
low-grade inflammation was confirmed by the small
increases in some pro-inflammatory cytokine titers (in-
cluding IL-6 and INF-γ). The levels of most of the cyto-
kines investigated, mainly in serum, were low, with no
statistically significant difference between groups. Never-
theless, serum IL-13, colonic IFN-γ and IL-4, and both
serum and colonic IL-6 and IL-22 were higher in DNBS
treated mice. IFN-γ is a Th1 cytokine and an important
activator of macrophages; it is involved in the regulation
of inflammation and in barrier dysfunction through the
redistribution and expression of TJ proteins [38]. The
pro-inflammatory Th1 cytokine IL-6 modulates the ex-
citability of submucosal neurons and increases colonic
secretory function. The cytokine IL-22 regulates various
processes linked to several autoimmune disorders [39]
exerting both antimicrobial and pro-inflammatory func-
tions. IL-4 is a Th-2 cytokine, canonical of IL-13 [40],
with stimulatory effects on B- and T-cells [41]; as well as
involvement in dichotomous regulation of Th cell differ-
entiation, IL-4 induces so-called alternative macrophage
activation [42]. IL-4 and IL-13 can decrease cellular
Figure 5 Cytokine concentrations in colon (A) and serum (B) in the DNBS micro-inflammation model. Control non-inflamed (EtOH-PBS),
control inflamed (DNBS-PBS), bacteria-free culture medium (DNBS-LYBHI), F. prausnitzii strain A2-165 (DNBS-Fprau), and F. prausnitzii A2-165 SN
(DNBS-SN) groups. Experiments were performed at least in duplicate. Comparisons involved the non-parametric Kruskal-Wallis test was used
followed by a Dunn’s Multiple Comparison test. *p < 0.05 vs. DNBS-PBS, +p < 0.05 (n = 16 mice per group).
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in vivo [43,44]. Our findings for the cytokines are diffi-
cult to interpret as they seem to involve both Th-1
and Th-2 immune responses as well as effects in the
Th-17/Th-22 subset. This is not surprising because
the particular inflammatory environment of our model
could be the consequence of cross-regulation between
all these possible pathways [11]. Although the profile
of cytokines after chronic low dose DNBS challenge is
not completely characterized, the altered cytokine
profiles we document here in DNBS-treated mice and
untreated control mice confirm mild immunological
dysfunctions in the model. Furthermore, both F.prausnitzii and SN treatments had beneficial effects
on indicators of immune status.
As IBD patients in remission often exhibit gut dys-
function [45], we therefore chose to study colonic per-
meability and serotonin levels as functional markers in
our model. Treatment with either F. prausnitzzi or its
SN normalized in vivo permeability, suggesting that
overall permeability was improved. SN also improved
permeability in vitro suggesting that the SN acts to pro-
tect the paracellular pathway in DNBS-challenged mice.
This result is consistent with the findings by Carlssonn
et al. that F. prausnitzii SN counteracted the negative
effects of DSS challenge on colonic permeability [46].
Figure 6 Serotonin concentrations in colon (A) and colon contents (B) in the DNBS micro-inflammation model. Control non-inflamed
(EtOH-PBS), control inflamed (DNBS-PBS), bacteria-free culture medium (DNBS-LYBHI), F. prausnitzii strain A2-165 (DNBS-Fprau), and F. prausnitzii
A2-165 SN (DNBS-SN) groups. Experiments were performed at least in duplicate.Comparisons involved the non-parametric Kruskal-Wallis test was
used followed by a Dunn’s Multiple Comparison test. *p < 0.05 vs. DNBS-PBS, +p < 0.05 (n = 16 mice per group for analysis of colon samples and
n = 8 mice per group for analysis of colon content samples).
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ied by a reduction in the expression of apical junction
proteins. Treatment with either F. prausnitzii or its SN
restored the levels of Claudin-4 and the junctional adhe-
sion molecule F11r (JAM1). Overall, our results suggest
that the protective effect of F. prausnitzii and its SN
may be the consequence, at least in part, of an effect on
tight junctions mediated through certain tight junction
proteins. Other common biomarkers in gut dysfunction
are related to gut dysmotility [47]. Although serotonin
is not a direct marker of motility, it stimulates peristal-
sis, secretion, vasodilatation and sensory signaling in
the gut [48]. It also activates the immune cells to
produce pro-inflammatory mediators [49] being a link
between inflammation and functional symptoms. En-
terochromaffin cells (EC) containing serotonin transduce
chemical and mechanical stimuli from the intestinal
lumen by releasing the serotonin [50]. Serotonin select-
ive reuptake transporter (SERT), expressed on intestinal
enterocytes, terminates the action of 5-HT by eliminat-
ing it from the interstitial space [48]. Dysfunctional mu-
cosal serotonin signaling has been implicated in visceral
sensitivity and altered motility in IBD patients [50,51].
Colonic levels of 5-HT were high in DNBS-challenged
mice, both in colon tissue and content. This result is in
agreement with previous studies reporting altered levels
of this hormone in murine models of TNBS-induced in-
flammation and low grade inflammation [33]. Both F.
prausnitzii and its SN were able to restore the serotonin
level to normal. In T-cell-mediated models of inflamma-
tion, an increase in EC and a decrease SERT function
have been described [52]. The cytokines IFN-γ and IL-
13 (restored in both F. prausnitzii- and SN-treated mice)
are involved in the metabolism of 5-HT, IFN-γ decreases
SERT expression in human epithelial Caco-2 cells in vitro
[53], and IL-13 contributes to increasing EC numbers [52].
In agreement with what has been described for TNBS [54],we found lower SERT levels in DNBS-challenged mice.
Moreover, F. prausnitzii and its SN restored these levels to
normal. However, it is possible that the abundance of SERT
reflects the general status of the epithelium, and it is not
necessarily a direct consequence of the actions of F praus-
nitizii or its SN. Indeed, the LYBHI medium may have an
effect on SERT. This is not the first time that culture media
(LYBHI or MRS) have been reported to show intrinsic
anti-inflammatory properties in vivo and in vitro [25];
this is presumably due to some of the components of
the medium, as previously observed with MRS culture
medium [55].
Conclusion
Chronic low-grade inflammation is common in patients
with IBD in clinical remission as well as in IBS patients
[15,28]. Patients with histological inflammation at baseline
are at increased risk of clinical relapse, hospitalization, sur-
gery, and colon cancer in observational longitudinal studies
[15]. It is widely recognized that microbiota can impact on
gut homeostasis. Our study proposes that F. prausnitzii,
one of the major members of the gut microbiota, protects
from gut dysfunction-related symptoms in animal models.
In summary, we describe novel protective effects of both F.
prausnitzii and its SN on chronic low-grade inflammation,
in a murine model mimicking the relapsing low-grade in-
flammatory conditions present in some IBD patients under
remission. This bacterium exerts different beneficial effects
in terms of cytokine levels, gut permeability and serotonin
pathway. Furthermore, our results suggest that the protect-
ive effect of F. prausnitzii and its SN may be the conse-
quence, at least in part, of barrier enhancement through
certain tight junction proteins. These results provide fur-
ther evidence of the potential of F. prausnitzii as a novel
probiotic for gut-dysfunction management. Future studies
will need to be performed to validate the described benefi-
cial effect in patients gut dysfunction and low grade
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whether disease associated dysbiosis is corrected, or
whether the effect is independent of a modulation of
the gut microbiota.
Methods
Bacterial strains and growth conditions
Faecalibacterium prausnitzii strain A2-165 (DSMZ col-
lection, Braunschweig, Germany) (DSM N° 17677) was
grown in LYBHI medium (brain-heart infusion medium
supplemented with 0.5% yeast extract) (Difco, Detroit,
USA) supplemented with 1 mg/ml cellobiose (Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland), 1 mg/ml
maltose (Sigma-Aldrich), and 0.5 mg/ml cysteine
(Sigma-Aldrich) at 37°C in an anaerobic chamber as
previously described [22]. The supernatant of F. praus-
nitzii cultures (SN) were recovered by centrifugation
filtered through 0.45 μm pore-size filters (VWR, Haasrode,
Belgium) and stored at −80 C until use.
Animals
Male C57BL/6 mice (6–8 weeks old) (Janvier, Le Genest
Saint Isle, France or Taconic mice New York, USA) were
maintained either at the animal care facilities of the Na-
tional Institute of Agricultural Research (IERP, INRA,
Jouy-en-Josas, France) or at the animal care facilities of
McMaster University (CAF, Hamilton, Ontario, Canada)
under specific pathogen-free conditions. Mice were housed
under standard conditions for a minimum of one week be-
fore experimentation. All experiments were performed in
accordance with European Community rules and approved
by the Animal Care Committee COMETHEA (Comité
d’Ethique en Expérimentation Animale du Centre INRA de
Jouy-en-Josas et AgroParisTech, Jouy en Josas, France) and
the Canadian Council on Animal Care Guidelines (CCAC).
Low grade-inflammation induction and F. prausnitzii
administration
The experimental protocol is detailed in Figure 1A.
Briefly, mice of approximately 20 g were fully anesthe-
tized by intraperitoneal (i.p.) injection of 150 μl of 0.1%
ketamine (Imalgene 1000, Merial, France) and 0.06%
xylazine (Rompun, Alcyon, France) and a 3.5 catheter
(French catheter, Solomon Scientific, France) attached to
a tuberculin syringe was inserted into the colon. A dose
of 100 mg/Kg of DNBS solution (ICN, Biomedical Inc.)
in 30% ethanol (EtOH) was then injected intrarectally
(i.r.). Control mice (without colitis) received only 30%
EtOH. Ten days after the DNBS acute period (the three
days following DNBS administration during which the
effects are greatest), 200 μl of 1X109 CFU of bacteria in
PBS, or PBS alone, or culture supernatant (SN) were ad-
ministered intragastrically, daily for 10 days (gavage
period). The DNBS administration was repeated 21 daysafter the first DNBS injection (recovery period) with a sec-
ond injection of 50 mg/Kg of DNBS solution. Weight loss
was monitored during 3 days following the second DNBS
injection to assess possible clinical signs of distress.
To confirm the absence of overt inflammation,
macroscopic and histological scores as well as myelo-
peroxidase (MPO) activity were determined as previ-
ously described [25].
Lipocalin-2 (Lcn-2) levels
Before the mice were sacrificed, blood samples were
obtained from the retro-orbital venous plexus, and
centrifuged for 10 min at 12,000 rpm and 4°C. Clear su-
pernatants (serum) were collected and stored at −20°C
until analysis. Serum samples were diluted in the kit-
recommended diluent (1% BSA in PBS), and Lcn-2 was
assayed using Duoset murine Lcn-2 ELISA kit (R&D
Systems, Minneapolis, MN) [36].
Cytokine assays
One centimeter samples of distal colon were recovered
and homogenized in an appropriate volume (to give
50 mg/ml) of Tris–HCl buffer containing protease inhib-
itors (Sigma-Aldrich) in a Tissue Lyser (Qiagen). The
samples were centrifuged for 20 min and the superna-
tants collected and frozen at −80°C until analysis. Blood
samples were obtained from the retro-orbital venous
plexus before the mice were killed and centrifuged, and
the sera stored at −80°C until analysis. IL-6, IL-10,
IFN-γ, TNF-α, IL-5, IL-2, IL-22, IL-1α, IL-13, IL-17, IL-
4, IL-27 and IL-12p70 were assayed with a cytometric
bead array system (Mouse Th1/Th2/Th17/Th22 13plex
Flowcytomix) (eBioscience, San Diego, USA).
Intestinal permeability in vitro and in vivo
Three days after the final DNBS challenge, intestinal
permeability in vitro was assessed by the Ussing cham-
ber technique as previously described (World Precision
Instruments, Sarasota, FL, USA) [56,57]. Two sections of
colon from each mouse were assessed. Tissue conduct-
ance (the passive permeability to ions) and mucosal-to-
serosal flux of the paracellular probe 51Cr-EDTA were
determined to assess barrier function and paracellular
permeability. 51Cr-EDTA flux was calculated as the aver-
age over a 2-h period and is expressed as %hot/cm2/hr.
Permeability in vivo was assessed using fluoroscein-
conjugated dextran (FITC-dextran 3000–5000 Da, Sigma-
Aldrich) as previously described [58]. Briefly, three days
after the second DNBS injection, 0.6 mg/g body
weight of FITC-dextran was administered to mice by
oral gavage and 3.5 h later, blood samples were ob-
tained from the retro-orbital venous plexus. Plasma
FITC levels were determined by fluorometry using a
microplate reader (Tecan, Lyon, France).
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Total RNA was isolated from 20–30 mg samples of colon
with an RNeasy Mini Kit (Qiagen). Column DNAse treat-
ment (Qiagen) was used to eliminate potential DNA con-
tamination. RNA quantity and quality were checked with a
NanoDrop aparatus (Thermo Scientific) and by agarose gel
electrophoresis. Only samples with intact RNA were used
for subsequent cDNA synthesis with iScript reverse tran-
scriptase (Bio-Rad): 500 μg of the total RNA preparation
was used for each sample. Quantitative real-time PCR
(qPCR) was performed with diluted cDNA (10x) in
triplicate and with an iQ5 Real-Time Detection System
(Bio-Rad). The reaction mix consisted of Sofast
Evagreen Supermix (Bio-Rad), primers at 0.5 μM
(Additional file 2: Table S1), and 2 μL of diluted cDNA.
Values are expressed as relative fold differences normalized
to a housekeeping gene, Gapdh, by the 2-ΔΔCTmethod. All
procedures were performed according to the manu-
facturers’ instructions.
Protein expression of apical junctional proteins was
evaluated also using immunofluorescence. Colon sam-
ples were embedded in Tissue-Tek OCT (Sakura,
Torrance, CA). Frozen sections were then cut (5 μm),
fixed with 3% paraformaldehyde (PFA) for 15 minutes at
20°C, and blocked with phosphate-buffered saline (PBS)/
bovine serum albumin at 2% for 1 hour. Samples were
immune-stained overnight with E-cadherin antibody
(1:1000 dilution, BD Pharmaceutical), Occludin (1:200,
Invitrogen), Claudin 4 (1:200, Invitrogen), F11r (1:100,
R&D) and 1 hour with appropriate secondary antibody
(1:250 dilution, Molecular Probes). Representative pic-
tures from each animal were taken with the same expos-
ure time.
Colonic serotonin assays
One centimeter-long sections of colon were recovered
and homogenized (50 mg/ml) in PBS buffer containing
protease inhibitors and Serotonin Stabilizer (LDN,
Nordhon, Germany) in a Tissue Lyser (Qiagen). The
colon contents were recovered by washing with 1 ml of
PBS buffer containing protease inhibitors and Serotonin
Stabilizer (LDN) and centrifuged; the supernatant stored at
−80°C until analysis. Serotonin concentrations were deter-
mined using a Serotonin Research ELISA (LDN) according
to the manufacturer’s instructions.
Serotonin transporter (SERT) expression in colon
Total RNA was extracted from 1 cm-long sections of
colon homogenized in a TissueLyser, by the guanidinium
thiocyanate method [59]. RNA concentration and purity
were determined using a Nanodrop ND-1000 apparatus
(Thermo Scientific) and the RNA Integrity Number
(RIN) was checked using an Agilent 2100 bioanalyzer(ICE platform, INRA, Jouy-en-Josas, France) and an
RNA 6000 Nano LabChip® kit (Agilent technologies).
Reverse transcription was performed with 0.1 to 5 μg of
RNA of each sample using the High-Capacity cDNA
Archive Kit (Applied Biosystems, France) according to
the manufacturer’s instructions. The absence of PCR in-
hibition was confirmed for each cDNA sample with the
TaqMan® Exogenous Internal Positive Control (Applied
Biosytems, France). The cDNA products were analyzed
in triplicate by RT-qPCR with an ABI PRISM 7000
Sequence Detection System and the 7000 system software
version 1.2.3 (Applied Biosytems). Several genes were ana-
lyzed using TaqMan Gene Expression Assays (Applied Bio-
systems, France), including Slc6a4 (Mm00439391_m1) and
gapdh (Mm99999915_g1), used as a reference. The results
obtained were normalized to the value for gapdh rRNA and
compared with the mean target gene expression in the
ETOH-PBS group as the calibrator sample. The following
formula was used: fold change = 2-ΔΔCt, where ΔΔCt
threshold cycle (Ct) equals (target Ct - reference Ct) of
sample minus (target Ct - reference Ct) of the calibrator.
Statistical analysis
GraphPad software (GraphPad Sofware, La Jolla, CA,
USA) was used for statistical analysis. Results are pre-
sented as bar graphs or dot plots with means +/− SEM.
Comparisons involved the non-parametric Kruskal-
Wallis test was used, followed by a Dunn’s Multiple
Comparison test. A p value of less than 0.05 was consid-
ered significant.
Additional files
Additional file 1: Figure S1. Effect of F. prausnitzii on apical junction
proteins in a DNBS-induced low-grade inflammation model. Sections of the
distal colon were stained for Claudin-4, Fr11, occludin (green) and E-cadherin
(red) expression. Nuclei (DAPI; blue). Original magnification X20. Representative
images from control non-inflamed (EtOH-PBS), control inflamed (DNBS-PBS),
bacteria-free culture medium (DNBSLYBHI), F. prausnitzii strain A2-165
(DNBS-Fprau), and F. prausnitzii A2-165 SN (DNBS-SN) groups.
Additional file 2: Table S1. Primers used in this study.
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